Emergent BioSolutions faces declining revenues, increasing competition, and limited growth potential, leading to a sell rating due to poor risk-reward profile. NARCAN, their main revenue generator, is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback